How India Exports Busulfan to the World

Busulfan, marketed under the trade name Busulfex, received FDA approval on February 4, 1999, for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for busulfan, indicating the presence of generic versions in the U.S. market. As of March 2026, there are no active FDA import alerts specifically targeting busulfan, suggesting compliance with regulatory standards.

The U.S. market's demand for busulfan is reflected in its position as the third-largest importer of the drug from India, accounting for 11.1% of total exports. This underscores the importance of maintaining stringent quality and regulatory compliance among the 33 active Indian exporters to ensure continued market access.

In the European Union, busulfan has been authorized for use as a conditioning treatment prior to hematopoietic progenitor cell transplantation. Notably, Busilvex, a busulfan product, had its marketing authorization withdrawn in January 2023 at the request of the marketing authorization holder, Pierre Fabre Medicament, due to commercial reasons. (ema.europa.eu) Despite this withdrawal, generic versions of busulfan remain authorized and marketed within the EU.

The United Kingdom, having exited the EU, continues to regulate busulfan through the Medicines and Healthcare products Regulatory Agency (MHRA). Manufacturers exporting busulfan to the UK must adhere to the UK's Good Manufacturing Practice (GMP) standards, which align closely with EU GMP requirements.

Busulfan is included in the World Health Organization's Model List of Essential Medicines, underscoring its critical role in healthcare systems worldwide. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and formulation across different regions.

In India, busulfan is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for busulfan, allowing market-driven pricing. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of busulfan, ensuring compliance with national regulations.

The primary patents for busulfan have expired, leading to the availability of generic versions and increased competition in the market. This competitive landscape is reflected in the presence of 33 active Indian exporters supplying busulfan to 44 destination countries.

In April 2025, the European Medicines Agency (EMA) conducted a Periodic Safety Update Report Single Assessment (PSUSA) for busulfan, resulting in variations to the terms of marketing authorizations to enhance safety information. (ema.europa.eu)

In January 2023, the marketing authorization for Busilvex was withdrawn in the EU at the request of the marketing authorization holder, Pierre Fabre Medicament, due to commercial reasons. (ema.europa.eu)

In September 2024, the FDA issued a safety communication regarding the use of busulfan, highlighting the need for monitoring due to potential adverse effects.

In November 2025, the NPPA in India reviewed the pricing of busulfan, resulting in a recommendation to maintain current market-driven pricing without imposing a ceiling price.

In February 2026, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of busulfan as a critical medication for conditioning treatment prior to hematopoietic progenitor cell transplantation.

Busulfan, a chemotherapy agent, is primarily manufactured in India, which serves as a significant hub for Active Pharmaceutical Ingredient (API) production. However, the production of Busulfan APIs often relies on Key Starting Materials (KSMs) sourced from China. China controls approximately 70–80% of the global KSM supply, making it a dominant player in this sector. This dependency creates a strategic chokepoint; any disruption in Chinese KSM production can directly impact the synthesis of APIs in India, leading to potential shortages of Busulfan.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, the closure of the Strait of Hormuz disrupted the supply of petrochemical feedstocks essential for pharmaceutical manufacturing. This disruption affected the availability of solvents and reagents necessary for API synthesis, including those for Busulfan. Such events underscore the fragility of the supply chain, where reliance on specific regions for critical raw materials can lead to significant production challenges.

The export market for Busulfan from India is highly concentrated. According to TransData Nexus's proprietary trade data, the top five exporters account for 94.0% of total exports, with INTAS PHARMACEUTICALS LIMITED alone holding a 40.4% share. This high level of supplier concentration poses a significant single-source risk; any operational or regulatory issues affecting these key exporters could disrupt the global supply of Busulfan.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce dependency on imports. While this initiative is a step towards diversifying the supplier base, its impact on Busulfan production remains to be fully realized.

Geopolitical tensions have recently led to significant disruptions in global shipping routes. In February 2026, the closure of the Strait of Hormuz halted oil tanker movements, affecting not only energy supplies but also the transportation of pharmaceuticals from India. Similarly, instability in the Red Sea and the Suez Canal has forced shipping companies to reroute vessels around the Cape of Good Hope, adding delays and increasing transportation costs.

These disruptions have had a cascading effect on the pharmaceutical supply chain, leading to delays in the delivery of critical drugs like Busulfan. The U.S. Food and Drug Administration (FDA) has been actively monitoring these developments to prevent and mitigate potential drug shortages. However, the ongoing nature of these geopolitical conflicts continues to pose a threat to the timely availability of essential medications.

• Diversify KSM Sourcing: Identify and qualify alternative suppliers for Key Starting Materials beyond China to reduce dependency and enhance supply chain resilience.

• Expand Supplier Base: Encourage the development of additional Busulfan API manufacturers within India and other regions to decrease reliance on a limited number of exporters.

• Enhance Inventory Management: Increase safety stock levels of Busulfan and its raw materials to buffer against potential supply disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact shipping routes and proactively adjust logistics strategies accordingly.

• Invest in Domestic Manufacturing: Support initiatives like the PLI scheme to strengthen domestic production capabilities for APIs and KSMs, reducing reliance on imports.

RISK_LEVEL: HIGH